Allspring中小型核心主動型ETF ASCE 深 滬
等待開盤 11-04 09:30:00 美东时间
32.95
+0.510
+1.57%
華盛通- 最 高33.00
- 今 開32.74
- 成交量 25.56万股
- 最 低 32.5656
- 昨 收 32.44
- 總市值 2.72亿
- 52周最高 36.3096
- 市盈率 靜 --
- 換手率 3.10%
- 52周最低 24.5889
- 委 比 46.67%
- 總股本 825.30万
- 歷史最高 36.3096
- 量 比 1.02
- 振 幅 1.34%
- 歷史最低 24.0619
- 每 手 1
- 風險率 3.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amarin三季度实现盈利 得益于成本削减抵消营收下滑
Amarin公布2026年第三季度净利润为20万美元，运营成本的降低抵消了美国市场VASCEPA收入的下滑，同时国际市场需求实现增长。
10-29 00:01
Amarin (AMRN) 2026年第三季度业绩电话会：随着国际需求增长重返盈利
Amarin 2026年第三季度业绩电话会议：营收达3960万美元，录得两年来首次季度盈利，经营现金流为900万美元，且国际市场需求强劲。
10-28 21:51
Amarin (AMRN) Q3 2026 Earnings Call: Profitability Returns as International Demand Grows
Amarin Q3 2026 earnings call: $39.6 million revenue, first quarterly profit in two years, $9 million operating cash flow and strong international demand.
10-28 21:50
CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union
CAMP4 Therapeutics received EU approval to initiate a global Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder, following clearances in the UK, Australia, and Argentina. The ASCEND trial aims to enroll patients globally, with first dosing expected in 4Q 2026. CMP-002 is designed to increase SYNGAP1 protein levels in patients with this rare genetic disorder, offering potential disease-modifying benefits.
10-27 12:00
ALLSPRING AMONG FIRST ASSET MANAGERS TO INTRODUCE ETF SHARE CLASSES
Three Fixed Income ETF Share Classes Start Trading Today CHARLOTTE, N.C., Oct. 21, 2026 /PRNewswire/ -- Allspring Global Investments™ (Allspring), a global asset management firm with more t...
10-21 20:30
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
ADMA Biologics announced the publication of a study detailing improvements in their IVIG manufacturing process, which effectively removes procoagulant impurities while maintaining immunoglobulin quality and increasing IgG yield. No thromboembolic events were reported for ADMA IVIG products during the postmarketing surveillance period. The optimized process enhances patient safety and product quality, supporting ADMA's commitment to advancing biop...
10-15 11:00
Conduent Investor Day Highlights ASCEND Long-Term Strategy
Conduent ( ($CNDT) ) has shared an announcement. On September 30, 2026, Conduen...
09-30 18:48
ASCE GYO Redirects TL 560 Million to Ankara Property Acquisitions
ASCE GAYRIMENKUL YATIRIM ORTAKLIGI A.S. ( ($TR:ASGYO) ) has provided an update....
09-30 00:15
CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder
CAMP4 Therapeutics Corporation ( ($CAMP) ) has shared an update. On September 2...
09-29 05:25
ASCE Real Estate Investment Trust Launches Share Buy-Back Program
ASCE GAYRIMENKUL YATIRIM ORTAKLIGI A.S. ( ($TR:ASGYO) ) just unveiled an update...
09-29 01:21
